Total: $610.9M | ||||
Company |
Location |
Amt. (M) |
Details |
Date |
Applied Genetic Technologies Corp. |
Gainesville, Fla. |
$37.5 |
Applied Genetic raised $37.5M in a Series B financing led by Alta Partners and S.R. One Ltd.; other investors were Osage University Partners, InterWest, Intersouth Partners and MedImmune Ventures |
11/20/12 |
Auspex Pharmaceuticals Inc. |
La Jolla, Calif. |
$25 |
Auspex raised $25M in a Series D round led by Panorama Capital, with existing investors Thomas, McNerney & Partners, CMEA Capital and Sloan Biotech Fund also taking part. |
11/9/12 |
Avexxin AS |
Trondheim, Norway |
ND |
Avexxin closed a Series B financing round involving new and existing shareholders. |
11/13/12 |
Cardioxyl Pharmaceuticals Inc. |
Chapel Hill, N.C. |
$28 |
Cardioxyl raised $28M in a Series B financing led by OrbiMed Advisors; other investors were Osage University Partners, New Enterprise Associates and the Aurora Funds |
11/14/12 |
Edison Pharmaceuticals Inc. |
Mountain View, Calif. |
$20 |
Edison raised $20M in a Series F round led by Mitsui & Co. Global Investment Inc. |
11/28/12 |
Genoa Pharmaceuticals Inc. |
San Diego |
$1.2 |
Genoa raised $1.2M in a private financing |
11/9/12 |
Intarcia Therapeutics Inc. |
Hayward, Calif. |
$210 |
Intarcia completed two financings with total proceeds of $210M consisting of $160M from a preferred stock private placement and $50M from a private debt placement; investors were New Enterprise Associates Inc., New Leaf Venture Partners and Venrock, along with The Baupost Group LLC, Farallon Capital Management LLC; Morgan Stanley acted as sole placement agent for the debt and lead placement agent for the equity, with Leerink Swann LLC acting as co-placement agent on the equity |
11/16/12 |
Integra Holdings |
Jerusalem |
$7 |
Integra, a newly formed subsidiary of Yissum Research Development Co. Ltd., closed a $7M first round of financing |
11/1/12 |
Kiadis Pharma BV |
Amsterdam, the Netherlands |
€10 ($12.8) |
Kiadis raised $12.8M in a round led by LSP (Life Sciences Partners), and supported by a large investment from DFJ-Esprit; other investors were Alta Partners, Quest for Growth and NOM |
11/21/12 |
Lanthio Pharma BV |
Groningen, the Netherlands |
€4.8 ($6.2) |
Lanthio raised $6.2M in a Series A round with MorphoSys AG participating, along with BioGeneration Ventures and INKEF Capital, as well as Hanzepoort |
11/28/12 |
MabVax Therapeutics Inc. |
San Diego |
$5.25 |
MabVax closed the first tranche in a Series B financing led by Numoda Capital Innovations and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund, for an aggregate investment of $5.25 million |
11/21/12 |
NanoBio Corp. |
Ann Arbor, Mich. |
$11 |
NanoBio raised $11M in a Series C financing, including full participation from its existing investor syndicate |
11/29/12 |
Pearl Therapeutics Inc. |
Redwood City, Calif. |
$65 |
Pearl raised $65M in a Series D financing round; investors were 5AM Ventures, Clarus Ventures and New Leaf Venture Partners |
11/14/12 |
Resolve Therapeutics LLC |
Seattle |
$5.8 |
Resolve raised $5.8M in a Series B equity financing led by previous investor New Science Ventures, with participation of WRF Capital and Easton Capital |
11/2/12 |
Rhythm Pharmaceuticals Inc. |
Boston |
$8 |
Rhythm added $8M to its Series B financing, for a total of $33 million; investors were Pfizer Venture Investments, MPM Capital, New Enterprise Associates, Third Rock Ventures and Ipsen |
11/28/12 |
Rib-X Pharmaceuticals Inc. |
New Haven, Conn. |
$67.5 |
Rib-X raised $67.5M in a Series 2 preferred stock financing led by Vatera Healthcare Partners; other investors were Warburg Pincus, ABS Ventures and Vox Equity Partners |
11/30/12 |
TauRx Pharmaceuticals Ltd. |
Singapore |
$31.5 |
TauRx raised $31.5M through a tranche of a $111.8M equity investment by Genting Management (Singapore) Pte. Ltd. |
11/21/12 |
TxCell SA |
Valbonne, France |
€12.4 ($16.1) |
TxCell raised $16.1M in a Series C round led by the InnoBio fund, managed by Paris-based CDC Entreprises; existing investors Auriga Partners and Seventure Partners also participated |
11/28/12 |
Visterra Inc. |
Cambridge, Mass. |
$26 |
Visterra raised an additional $13M to completed a $26M Series A financing, with the Bill & Melinda Gates Foundation and Omega Funds participating with existing investors Polaris Venture Partners, Flagship Ventures and Lux Capital |
11/12/12 |
Ziarco Ltd. |
Canterbury, UK |
$27 |
Ziarco received $27M through a Series A round led by Biotechnology Venture Fund LP and including Pfizer Venture Investments |
11/5/12 |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. | ||||